MX355054B - Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo. - Google Patents

Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.

Info

Publication number
MX355054B
MX355054B MX2013010331A MX2013010331A MX355054B MX 355054 B MX355054 B MX 355054B MX 2013010331 A MX2013010331 A MX 2013010331A MX 2013010331 A MX2013010331 A MX 2013010331A MX 355054 B MX355054 B MX 355054B
Authority
MX
Mexico
Prior art keywords
hig2
same
epitope peptide
vaccines containing
urlc10
Prior art date
Application number
MX2013010331A
Other languages
English (en)
Spanish (es)
Inventor
Tsunoda Takuya
Ohsawa Ryuji
Yoshimura Sachiko
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX355054B publication Critical patent/MX355054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013010331A 2008-08-19 2009-08-14 Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo. MX355054B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8997208P 2008-08-19 2008-08-19
PCT/JP2009/003897 WO2010021112A1 (en) 2008-08-19 2009-08-14 Hig2 and urlc10 epitope peptide and vaccines containing the same

Publications (1)

Publication Number Publication Date
MX355054B true MX355054B (es) 2018-04-03

Family

ID=41707003

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011001883A MX337756B (es) 2008-08-19 2009-08-14 Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
MX2013010331A MX355054B (es) 2008-08-19 2009-08-14 Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011001883A MX337756B (es) 2008-08-19 2009-08-14 Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.

Country Status (16)

Country Link
US (1) US9119800B2 (enExample)
EP (1) EP2328600B9 (enExample)
JP (1) JP5633025B2 (enExample)
KR (1) KR101713581B1 (enExample)
CN (2) CN104958753B (enExample)
AU (1) AU2009283763B2 (enExample)
BR (1) BRPI0917391A2 (enExample)
CA (1) CA2734467C (enExample)
DK (1) DK2328600T3 (enExample)
ES (1) ES2566011T3 (enExample)
IL (1) IL211117A (enExample)
MX (2) MX337756B (enExample)
RU (1) RU2529373C2 (enExample)
SG (2) SG10201610206VA (enExample)
TW (2) TWI543767B (enExample)
WO (1) WO2010021112A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
JP6255594B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
US10576097B2 (en) * 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
RU2758112C2 (ru) 2015-08-10 2021-10-26 Торэй Индастриз, Инк. Индуктор иммунитета
KR20180033585A (ko) 2015-08-12 2018-04-03 온코세라피 사이언스 가부시키가이샤 Depdc1-유래 펩티드 및 이를 포함하는 백신
IL310182A (en) 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures of chimeric antibody/T-cell receptor and uses thereof
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU6318300A (en) * 1999-08-05 2001-03-05 Kyogo Itoh Tumor antigen
WO2001023426A2 (en) 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
CA2570392A1 (en) * 2004-06-21 2005-12-29 Green Peptide Co., Ltd. Peptide vaccine for cancer therapy
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
CA2599875A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
JP2009502112A (ja) 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
JP5116150B2 (ja) * 2005-09-07 2013-01-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP4840858B2 (ja) * 2006-03-16 2011-12-21 学校法人慶應義塾 癌ワクチン
ATE509096T1 (de) 2006-06-16 2011-05-15 Onco Therapy Science Inc Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US20100291091A1 (en) 2007-07-30 2010-11-18 ONCOTHERAPY SCIENCE ,inc. Cancer associated gene ly6k
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
CN104958753B (zh) 2018-09-25
SG193806A1 (en) 2013-10-30
AU2009283763A2 (en) 2011-07-07
KR101713581B1 (ko) 2017-03-08
JP2012500184A (ja) 2012-01-05
TWI543767B (zh) 2016-08-01
EP2328600A1 (en) 2011-06-08
CA2734467A1 (en) 2010-02-25
US20110243973A1 (en) 2011-10-06
CN104958753A (zh) 2015-10-07
TW201019952A (en) 2010-06-01
US9119800B2 (en) 2015-09-01
EP2328600B1 (en) 2016-01-27
KR20110045052A (ko) 2011-05-03
CN102186491B (zh) 2015-06-10
MX2011001883A (es) 2011-03-29
WO2010021112A1 (en) 2010-02-25
CA2734467C (en) 2017-10-03
IL211117A0 (en) 2011-04-28
SG10201610206VA (en) 2017-01-27
AU2009283763A1 (en) 2010-02-25
IL211117A (en) 2017-03-30
HK1157204A1 (zh) 2012-06-29
BRPI0917391A2 (pt) 2015-12-01
JP5633025B2 (ja) 2014-12-03
CN102186491A (zh) 2011-09-14
DK2328600T3 (en) 2016-03-29
RU2529373C2 (ru) 2014-09-27
EP2328600B9 (en) 2016-07-13
RU2011110376A (ru) 2012-09-27
TWI580431B (zh) 2017-05-01
ES2566011T3 (es) 2016-04-08
TW201500055A (zh) 2015-01-01
AU2009283763B2 (en) 2014-06-19
EP2328600A4 (en) 2013-03-06
MX337756B (es) 2016-03-17

Similar Documents

Publication Publication Date Title
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
NZ708990A (en) Method for activating helper t cell
IN2014KN01715A (enExample)
MX2010002002A (es) Peptido foxm1 y agente medicinal que lo contiene.
NZ618391A (en) Antigenic tau peptides and uses thereof
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
RU2010110564A (ru) Пептид cdca1 и включающее его фармацевтическое средство
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP2014502961A5 (enExample)
RU2009129531A (ru) Вакцины на основе пептида foxp3
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
PH12014500720A1 (en) Topk peptides and vaccines including the same
WO2013171661A3 (en) Adjuvant formulations and methods
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
GB201018125D0 (en) Peptide
PH12013501105A1 (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
NZ593200A (en) Peptide adjuvants
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.